Patient education › Upper tract urothelial cancer
Upper tract urothelial cancer (UTUC)
UTUC is urothelial cancer arising in the lining of the kidney's collecting system or the ureter. It shares a cell type with bladder cancer, but treating it often costs a kidney, which changes almost every decision.
Walk in prepared
UTUC is uncommon, and decisions involve balancing cancer control against kidney function. Coming in organized helps you weigh that properly.
Dr. Weiner uses WellPrept to help patients gather their records and write down their questions ahead of time. It is free, takes about ten minutes, and you do not need to be his patient to use it. If you are seeing another urologist, or preparing for a second opinion anywhere, it works just as well.
Organize your records and questions before you sit down. Free, and yours to keep whichever doctor you see.
Not simply bladder cancer higher up
The urinary tract is lined by the same cell type from the kidney down to the urethra, so UTUC and bladder cancer look related. In practice they behave differently. UTUC is rare, making up somewhere around five to ten per cent of urothelial cancers, and it tends to be found later and carries a worse outlook than bladder cancer stage for stage.
The reason decisions feel harder is anatomical. Standard surgery for high-risk UTUC removes the kidney, the whole ureter and a cuff of bladder, so cancer control and kidney function pull against each other in a way they do not in the bladder.
How it is worked up
The workup usually involves a CT scan with contrast that includes delayed images to outline the drainage system, a cystoscopy to check the bladder at the same time, and ureteroscopy, where a fine telescope is passed up to look directly and take a biopsy. A urine sample is taken from the affected side specifically, rather than relying on a voided sample, because it gives a better yield.
Cystoscopy is not optional here. Bladder tumours are found alongside upper tract disease often enough that the bladder needs checking in the same episode.
Saving the kidney where it is safe to
For low-risk disease without unfavourable features, treating through the ureteroscope is first-line: the tumour is ablated with a laser or cautery, from below or occasionally through the back. Cancer outcomes are comparable to removing the kidney, and kidney function is far better preserved.
The catch is that it is rarely one procedure. A second look within about three months is expected, because residual or recurrent tumour is found in around half of people at that point, and it is repeated until things are clear. There is also a chemotherapy gel that can be instilled into the collecting system for small low-grade tumours, which achieves a complete response in a majority of patients, though ureteral narrowing is a recognized side effect.
When the kidney has to come out
Radical nephroureterectomy is recommended for high-risk disease, and when kidney-sparing treatment has failed. It removes the kidney, the entire ureter, and a cuff of bladder around where the ureter enters. That bladder cuff is not a detail: leaving it behind is associated with worse survival. For high-risk disease, the lymph nodes should be removed as well. For tumours confined to the lower ureter, removing just that segment and reimplanting the ureter is often preferred, and preserves meaningfully more kidney function.
Chemotherapy before, not after, when possible
This is the counterintuitive part worth understanding. Cisplatin needs reasonable kidney function. Once a kidney has been removed, many patients no longer qualify. So for high-risk disease, giving cisplatin-based chemotherapy before surgery is favoured, particularly if your kidney function is borderline. If chemotherapy was not given beforehand and the pathology shows invasive or node-positive disease, adjuvant chemotherapy afterwards clearly improves outcomes and should start within about three months. Immunotherapy has a role for some patients who cannot have cisplatin.
One practical trap: if your kidney is obstructed, your measured kidney function looks worse than it truly is. Relieving the obstruction and rechecking can move you back into the eligible group, so it is worth asking whether that has been done before anyone concludes you cannot have cisplatin.
The single dose into the bladder
After surgery, a single dose of chemotherapy instilled into the bladder reduces the chance of a bladder recurrence. It is a small intervention with a clear benefit and is easy to overlook.
Worth asking out loud
The kidney-versus-cancer trade-off is the heart of this. Make it explicit.
About my cancer
- Is my disease low risk or high risk, and what makes it so?
- Was a biopsy taken, and what did the cytology show?
- Has my bladder been checked at the same time?
- Are there unfavourable features on my imaging?
About saving the kidney
- Can this be treated through the ureteroscope?
- How many procedures is that likely to mean?
- Is instilled chemotherapy an option for me?
- If the kidney must come out, could a segment of ureter be removed instead?
About chemotherapy
- Should I have chemotherapy before surgery rather than after?
- Is my kidney function being measured after any obstruction is relieved?
- Will I get the single dose into the bladder after surgery?
- If chemotherapy comes afterwards, when should it start?
About afterwards
- How often will I need cystoscopy, and for how long?
- Has my tumour been tested for Lynch syndrome?
- Should my family be screened?
- What will my kidney function be, and should I see a nephrologist?
Sources and further reading
This page was written for patients and reviewed by Dr. Weiner. It reflects current professional guidelines, which are written for clinicians. The patient-facing versions below are free and often easier to read.
- Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline, American Urological Association.
- Urology A-Z, Urology Care Foundation.
- Urology Care Foundation, the AUA's patient education arm.
- NCCN Guidelines for Patients, free plain-language versions of the treatment guidelines.
This is general education, not medical advice. It cannot account for your imaging, your pathology, your other health conditions or what matters to you. Take it to your own doctor and work through it together. If anything here conflicts with what your urologist has told you, raise it with them directly rather than assuming either of us is wrong.
Last reviewed September 2026 by Adam B. Weiner, MD.